Detailed company information
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 04, 2026
Earnings Transcript for 2026 - Q1Released: May 04, 2026
Earnings Transcript for 2025 - Q4Released: Feb 19, 2026
Earnings Transcript for 2025 - Q3Released: Oct 30, 2025
Earnings Transcript for 2025 - Q2Released: Aug 06, 2025
Earnings Transcript for 2025 - Q1Released: May 01, 2025
Earnings Transcript for 2024 - Q4Released: Feb 21, 2025
Earnings Transcript for 2024 - Q3Released: Oct 31, 2024
Earnings Transcript for 2024 - Q2Released: Aug 03, 2024
Earnings Transcript for 2024 - Q1Released: May 06, 2024
Earnings Transcript for 2023 - Q4Released: Feb 16, 2024
Earnings Transcript for 2023 - Q3Released: Nov 07, 2023
Earnings Transcript for 2023 - Q2Released: Aug 04, 2023
Earnings Transcript for 2023 - Q1Released: May 07, 2023
Earnings Transcript for 2022 - Q4Released: Feb 23, 2023
Earnings Transcript for 2022 - Q3Released: Oct 27, 2022
Earnings Transcript for 2022 - Q2Released: Aug 07, 2022
Earnings Transcript for 2022 - Q1Released: May 08, 2022
Earnings Transcript for 2021 - Q4Released: Feb 24, 2022
Earnings Transcript for 2021 - Q3Released: Oct 28, 2021
Earnings Transcript for 2021 - Q2Released: Jul 31, 2021
Earnings Transcript for 2021 - Q1Released: May 09, 2021
Earnings Transcript for 2020 - Q4Released: Mar 01, 2021
Earnings Transcript for 2020 - Q3Released: Nov 08, 2020
STOK Stoke Therapeutics, Inc.
COGT Cogent Biosciences, Inc.
IDYA IDEAYA Biosciences, Inc.
PTGX Protagonist Therapeutics, Inc.
KROS Keros Therapeutics, Inc.
ANAB AnaptysBio, Inc.
RNA Atrium Therapeutics, Inc.
RVMD Revolution Medicines, Inc.
PCVX Vaxcyte, Inc.
CYTK Cytokinetics, Incorporated
TBPH Theravance Biopharma Inc
UTHR United Therapeutics Corporation
Dafinchi